These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 6155500)

  • 1. [Clinical studies on serum lipids in the patients with tumor of the prostate gland. 1st Report: Serum lipids and lipoprotein fraction levels in the patients with benign prostatic hypertrophy and prostatic cancer (author's transl)].
    Yoshida H; Shimada M; Imamura K
    Nihon Hinyokika Gakkai Zasshi; 1980 Jan; 71(1):51-8. PubMed ID: 6155500
    [No Abstract]   [Full Text] [Related]  

  • 2. [Clinical studies on serum lipids in the patients with tumor of the prostate gland. 2nd. Report. Changes of serum lipids and lipoprotein fractions during the treatment of estramustine phosphate disodium, hexestrol and diethylstilbestrol 4, 4-diphosphoric ester for the patients with prostatic cancer (author's transl)].
    Yoshida H; Shimada M
    Nihon Hinyokika Gakkai Zasshi; 1980 Jan; 71(1):59-69. PubMed ID: 6155501
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Clinical experience with oxendolone for treatment of benign prostatic hyperplasia. Clinical efficacy and effects on serum lipid and lipoprotein fraction levels].
    Yasukawa A; Nihira H; Matsuki S; Fujii M; Fujiwara H; Kitano T; Kodama M; Ukai R; Tado O; Sagami K
    Hinyokika Kiyo; 1984 Apr; 30(4):537-43. PubMed ID: 6207714
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum interleukin-11 in patients with benign prostatic hyperplasia and prostate cancer.
    Furuya Y; Nishio R; Junicho A; Nagakawa O; Fuse H
    Int Urol Nephrol; 2005; 37(1):69-71. PubMed ID: 16132763
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Testosterone levels in benign prostatic hypertrophy and prostate cancer.
    Mearini L; Costantini E; Zucchi A; Mearini E; Bini V; Cottini E; Porena M
    Urol Int; 2008; 80(2):134-40. PubMed ID: 18362481
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Plasma testosterone production rates in patients with prostatic cancer and benign prostatic hypertrophy.
    Isurugi K
    J Urol; 1967 May; 97(5):903-8. PubMed ID: 4164949
    [No Abstract]   [Full Text] [Related]  

  • 7. The value of the measurement of serum prostate specific antigen in patients with benign prostatic hyperplasia and untreated prostate cancer.
    Armitage TG; Cooper EH; Newling DW; Robinson MR; Appleyard I
    Br J Urol; 1988 Dec; 62(6):584-9. PubMed ID: 2464397
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Significance of variability of serum lipid levels in ischemic heart disease (author's transl)].
    Kusá O; Haviar V; Luknárová O
    Bratisl Lek Listy; 1974 Oct; 62(4):459-67. PubMed ID: 4422473
    [No Abstract]   [Full Text] [Related]  

  • 9. Serum lipid levels in benign prostatic hyperplasia.
    Lekili M; Müezzinoğlu T; Uyanik BS; Büyüksu C
    World J Urol; 2006 Jun; 24(2):210-3. PubMed ID: 16506048
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The comparison between vitamin d concentration in upper silesia patients with prostate cancer and with benign prostatic hyperplasia.
    Wieczorek K; Braczkowski RS; Skrzypek M; Stryjewski PJ; Kuczaj A; Al-Srory G
    J Biol Regul Homeost Agents; 2015; 29(1):207-11. PubMed ID: 25864760
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of percentage of free serum prostate-specific antigen to improve specificity of prostate cancer screening.
    Catalona WJ; Smith DS; Wolfert RL; Wang TJ; Rittenhouse HG; Ratliff TL; Nadler RB
    JAMA; 1995 Oct; 274(15):1214-20. PubMed ID: 7563511
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prolactin and prostate: a chronobiologic study.
    Selli C; Benvenuti M; Melone F; Romano S; Tarquini B
    Eur Urol; 1983; 9(2):109-12. PubMed ID: 6189717
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Prostate-specific antigen in cancer and benign prostatic hyperplasia].
    Kushlinskiĭ NE; Liubimova NV; Gorilovskiĭ LM
    Biull Eksp Biol Med; 1997 Sep; 124(9):327-30. PubMed ID: 9445619
    [No Abstract]   [Full Text] [Related]  

  • 14. [BIOMARKERS OF EARLY AND DIFFERENTIAL DIAGNOSIS OF PROSTATIC CANCER].
    Grygorenko VM; Danylets RO; Vikarchuk MV; Gorbahn LV; Klepko AV
    Klin Khir; 2017; (1):54-7. PubMed ID: 30272918
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Prostatic tumors. Detection by proton nuclear magnetic resonance spectroscopy of plasma lipoproteins].
    Nabholtz JM; Tremeaux JC; Rossignol A; Farnier M; Gambert P; Briet S; Guerrin J
    J Urol (Paris); 1989; 95(4):209-12. PubMed ID: 2477463
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum-to-urinary prostate-specific antigen ratio in patients with benign prostatic hyperplasia and prostate cancer.
    Hillenbrand M; Bastian M; Steiner M; Zingler C; Müller M; Wolff JM; Seiter H; Schuff-Werner P
    Anticancer Res; 2000; 20(6D):4995-6. PubMed ID: 11326656
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum and urinary prostatic inhibin-like peptide in benign prostatic hyperplasia and carcinoma of prostate.
    Teni TR; Sheth AR; Kamath MR; Sheth NA
    Cancer Lett; 1988 Dec; 43(1-2):9-14. PubMed ID: 2462465
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Blood lipid levels as indicators of risk in the epidemiology of ischaemic heart disease (author's transl)].
    Pokorný J; Jezková Z
    Sb Lek; 1974 Jan; 76(1):1-7. PubMed ID: 4842894
    [No Abstract]   [Full Text] [Related]  

  • 19. Serum pro-gastrin-releasing peptide (31-98) in benign prostatic hyperplasia and prostatic carcinoma.
    Nagakawa O; Furuya Y; Fujiuchi Y; Fuse H
    Urology; 2002 Sep; 60(3):527-30. PubMed ID: 12350511
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Insulin-like growth factor-binding protein-2 in patients with prostate carcinoma and benign prostatic hyperplasia.
    Ho PJ; Baxter RC
    Clin Endocrinol (Oxf); 1997 Feb; 46(2):145-54. PubMed ID: 9135695
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.